Progesterone Mechanism: How It Works in the Female Body and During HRT

What Progesterone Actually Does at the Molecular Level

Progesterone is a C-21 steroid synthesized from cholesterol, primarily in the corpus luteum during the luteal phase and in the placenta during pregnancy. At the molecular level, it binds intracellular progesterone receptors encoded by a single gene (PGR) that produces two major isoforms through alternative promoter use: PR-A (94 kDa) and PR-B (120 kDa). PR-B contains an additional 164-amino-acid N-terminal domain that functions as a transcriptional activator, while PR-A acts primarily as a repressor of other steroid receptors including the estrogen receptor, glucocorticoid receptor, and PR-B itself. [1]

Once progesterone binds PR-B, the receptor dimerizes, dissociates from heat-shock protein 90, and translocates to the nucleus. There it attaches to progesterone response elements (PREs) on target gene promoters, recruiting co-activators such as SRC-1 and p300/CBP to initiate or suppress transcription. The net effect in uterine epithelium is a shift from a proliferative to a secretory phenotype. Genes driving cell proliferation (cyclin D1, c-Myc) are suppressed, while genes supporting implantation (IGFBP-1, glycodelin) are upregulated. [2]

Beyond nuclear signaling, a membrane-associated receptor called PGRMC1 (progesterone receptor membrane component 1) mediates rapid non-genomic effects within seconds to minutes. PGRMC1 activates PI3K/Akt and MAPK cascades, contributing to anti-apoptotic effects in granulosa cells and neuroprotective signaling in astrocytes. This rapid pathway explains some of the acute mood and anxiety effects women notice within days of starting or stopping progesterone. [3]

Serum progesterone in the mid-luteal phase peaks at 10 to 35 ng/mL. After natural menopause, levels fall below 0.5 ng/mL, effectively eliminating tonic PR activation and allowing unopposed estrogen signaling in the endometrium. [4]

How Progesterone Protects the Endometrium

The clearest clinical application of progesterone's mechanism is endometrial protection in postmenopausal women using systemic estrogen.

Estrogen alone, administered without a progestogen to women with a uterus, raises endometrial cancer risk roughly 2- to 12-fold depending on dose and duration. Adding a progestogen for at least 12 days per calendar month reduces that risk to near or below baseline. The 2022 British Menopause Society guideline states: "Adequate progestogen must be used to protect the endometrium in all women with a uterus who take systemic estrogen therapy." [5]

The mechanism is direct. Estrogen (via ER-alpha) upregulates PR expression in endometrial stromal and epithelial cells, priming those cells for the antiproliferative switch that progesterone subsequently triggers. PR-A suppresses ER-alpha-driven gene transcription, lowering the expression of estrogen-responsive growth genes. PR-B simultaneously induces expression of 17-beta-hydroxysteroid dehydrogenase type 2, an enzyme that converts the active estradiol to the weaker estrone, further limiting local estrogenic stimulus. [2]

Sequential regimens (progesterone for 12 to 14 days per 28-day cycle) produce monthly withdrawal bleeds in most women but carry a slightly higher endometrial risk than continuous combined regimens (daily progesterone), which produce endometrial atrophy over 6 to 12 months. Continuous use of micronized progesterone 100 mg nightly has demonstrated endometrial safety in trials lasting up to 3 years. [6]

Oral vs. Transdermal Progesterone: First-Pass Metabolism Changes Everything

The route you choose changes the pharmacology of progesterone substantially. This distinction matters clinically.

Oral micronized progesterone undergoes extensive first-pass hepatic and intestinal metabolism. Roughly 40% is converted to allopregnanolone (3-alpha,5-alpha-tetrahydroprogesterone) and pregnanolone before reaching systemic circulation. [7] These neurosteroids are positive allosteric modulators of GABA-A receptors and produce anxiolytic and hypnotic effects. That is why many women report improved sleep quality specifically on oral progesterone taken at bedtime. A crossover RCT by Montplaisir et al. found that oral micronized progesterone 300 mg reduced polysomnographic sleep-onset latency by 14.2 minutes compared to placebo (P<0.01). [8]

The downside of first-pass conversion is lower bioavailability for endometrial protection via blood-borne progesterone. The 2014 Cochrane review (Warren et al.) noted that transdermal progesterone cream at standard commercial doses does not consistently reach serum concentrations sufficient for full endometrial protection, though intravaginal micronized progesterone (Utrogestan 200 mg or Crinone 8% gel) achieves high local endometrial concentrations via the "first uterine pass" effect even when systemic serum levels are modest. [9]

Transdermal gels and creams bypass hepatic first-pass conversion, delivering progesterone more directly into systemic circulation without generating the same neurosteroid load. Women who want cardiovascular and endometrial benefits without sedation may prefer a vaginal route for progesterone while taking systemic estrogen transdermally.

Choosing progesterone route: a clinical decision framework

| Goal | Preferred Route | Notes | |---|---|---| | Endometrial protection only | Oral or vaginal micronized progesterone | Vaginal if sedation is undesirable | | Sleep improvement + protection | Oral micronized progesterone 100 to 200 mg at bedtime | Allopregnanolone effect is dose-dependent | | Avoiding first-pass neurosteroids | Vaginal micronized progesterone (Utrogestan vaginally) | Systemic levels low; local endometrial levels high | | Lipid-neutral cardiovascular profile | Micronized progesterone (any route) vs. MPA | MPA attenuates HDL rise from estrogen; micronized progesterone does not [10] |

Progesterone Receptor Isoforms PR-A and PR-B: Why the Ratio Matters

The PR-A:PR-B ratio in target tissue is not fixed. It changes with age, estrogen exposure, and inflammation, and the ratio shifts the net biological response to progesterone.

In the normal endometrium, PR-B predominates during the follicular phase, driving secretory differentiation when progesterone arrives. In endometriosis lesions, PR-A is overexpressed and PR-B is significantly reduced, a pattern associated with progesterone resistance. Women with endometriosis often need higher progesterone doses or different progestogens (dienogest rather than micronized progesterone) precisely because their ectopic endometrial tissue cannot mount a normal PR-B-mediated response. [11]

In breast tissue, the isoform ratio is equally relevant. A 2006 study by Mote et al. (N=224 biopsy specimens) found that PR-A:PR-B ratios above 2:1 correlated with reduced apoptotic response to progesterone, a feature seen in a subset of ER-positive breast cancers. This is one mechanistic reason why the WHI (N=16,608) finding of increased breast cancer risk with conjugated equine estrogen plus medroxyprogesterone acetate (relative hazard 1.26 to 95% CI 1.00, 1.59) cannot be extrapolated to micronized progesterone, which may have a more favorable PR isoform-specific profile. [12]

Estrogen Receptor Decline at Menopause and What It Means for Progesterone Sensitivity

Estrogen and progesterone receptors are co-regulated. Estrogen upregulates PR expression in the uterus, breast, brain, and bone. As estradiol falls during the menopause transition, PR expression decreases proportionally. In the hypothalamic arcuate nucleus, ER-alpha density declines an estimated 30 to 40% within 12 months of the final menstrual period, contributing directly to loss of thermoregulatory set-point control and the onset of vasomotor symptoms. [13]

The clinical implication: progestogen given without any estrogen replacement has limited effect on many targets because PR expression has already declined. This is why "progesterone-only" approaches to managing menopausal vasomotor symptoms tend to be only modestly effective compared to combined estrogen-progestogen therapy. A 1999 RCT by Leonetti et al. tested transdermal progesterone cream vs. placebo for hot flashes and found a statistically significant but clinically modest reduction (83% vs. 19% reporting improvement, P<0.001), and the study was short (12 weeks) with limited blinding controls. [14]

When estrogen therapy is initiated first, it restores PR expression over 4 to 8 weeks, making subsequently added progesterone more pharmacologically active. This sequential priming is a practical reason why estrogen is introduced before or simultaneously with progesterone in most HRT protocols, rather than the reverse.

Testosterone in Women: Mechanism and Interaction With Progesterone

Testosterone is often framed as a male hormone, but ovarian theca cells and adrenal cells produce testosterone throughout a woman's life, with peak serum concentrations around 200, 300 pg/mL in the mid-20s. After natural menopause, total testosterone falls by approximately 50% and continues declining with age. [15]

Testosterone acts via the androgen receptor (AR), a nuclear receptor in the same steroid receptor superfamily as PR. After binding testosterone or its more potent metabolite dihydrotestosterone (DHT, converted by 5-alpha-reductase), the AR dimer binds androgen response elements (AREs) on target genes. In brain, bone, muscle, clitoris, and vaginal tissue, AR activation drives protein synthesis, tissue maintenance, and libido-related dopaminergic signaling. [16]

Testosterone and progesterone interact indirectly through several pathways. First, androgen receptor activation upregulates PR expression in some cell types, meaning adequate testosterone may sensitize endometrial and breast tissue to progesterone's effects. Second, both hormones compete for 5-alpha-reductase activity, the enzyme that converts testosterone to DHT and converts progesterone to 5-alpha-dihydroprogesterone (a different neurosteroid than allopregnanolone). Third, high-dose exogenous testosterone can be peripherally aromatized to estradiol, further upregulating PR. [17]

From a therapeutic standpoint, women receiving testosterone as part of HRT may show better PR-mediated endometrial response and may require attention to estradiol levels from aromatization. The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women recommends targeting serum total testosterone in the premenopausal physiological range (typically 15 to 70 ng/dL) and monitoring for androgenic side effects at 3 and 6 months. [18]

Progesterone's Neuroprotective and Cardiovascular Mechanisms

Progesterone exerts direct effects on the central nervous system and cardiovascular system that go beyond endometrial protection.

Neuroprotection. Progesterone and its neurosteroid metabolites (allopregnanolone, pregnanolone) cross the blood-brain barrier freely. Animal models consistently show progesterone reduces neuroinflammation after traumatic brain injury through PR-mediated suppression of NF-kB and through GABA-A-mediated reduction of excitotoxicity. A Phase 3 RCT (ProTECT III, N=882) tested intravenous progesterone in moderate-to-severe TBI but found no mortality benefit (OR 0.95 to 95% CI 0.69, 1.31), tempering some earlier enthusiasm. The authors noted the short therapeutic window may have limited effect. [19] Mechanistic work in human tissue continues to show that PGRMC1 signaling promotes oligodendrocyte myelination, which has potential implications for multiple sclerosis and cognitive aging.

Cardiovascular effects. The cardiovascular story depends entirely on which progestogen is used. Medroxyprogesterone acetate (MPA), the synthetic progestin used in the WHI, attenuates the HDL-C raising effect of estrogen by approximately 40% and promotes coronary artery spasm in primate models. Micronized progesterone does not share these properties. The E3N prospective cohort (N=80,377 French postmenopausal women, followed 8.1 years) found that transdermal estradiol combined with micronized progesterone carried no significant increase in venous thromboembolism risk (RR 0.9 to 95% CI 0.6, 1.5), while oral estrogen plus synthetic progestin was associated with significantly elevated risk (RR 1.7 to 95% CI 1.1, 2.8). [20]

This differential risk profile is thought to arise from the fact that micronized progesterone, unlike MPA, does not activate glucocorticoid receptors or androgenic pathways, preserving endothelial nitric oxide synthase activity and preventing the pro-thrombotic changes in coagulation factors that MPA promotes. [10]

Dosing, Timing, and Monitoring in Clinical Practice

Standard oral micronized progesterone (Prometrium, Utrogestan) doses used in postmenopausal HRT are 200 mg nightly for 12 to 14 days per 28-day cycle in sequential regimens, or 100 mg nightly continuously. Intravaginal administration (Utrogestan 200 mg vaginally) achieves comparable endometrial protection with lower serum levels and is the preferred route in women who experience excessive sedation on oral dosing. [6]

Serum progesterone measurement is not routinely required for women on oral or vaginal micronized progesterone because the endometrial response, not serum level, is the clinical outcome of interest. An endometrial biopsy is indicated if unscheduled bleeding persists beyond 6 months on a continuous regimen or if sequential bleeding becomes heavy and irregular. [5]

For women on injectable or subcutaneous pellet progesterone, periodic serum progesterone levels (target: follicular-phase equivalent, roughly 0.5 to 2 ng/mL between doses for non-pregnant postmenopausal use) can help guide dosing intervals. Salivary progesterone assays are not standardized for clinical decision-making and are explicitly not recommended by the North American Menopause Society. [21]

Women with a history of significant hepatic impairment should avoid oral progesterone because first-pass metabolism is impaired, leading to unpredictably elevated serum levels. Vaginal or transdermal routes are preferred in this population.

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727, 4-year duration) compared oral conjugated equine estrogen plus oral progesterone against transdermal estradiol plus vaginal progesterone gel and found that both regimens maintained endometrial safety with no hyperplasia cases in either arm, while the transdermal group showed modestly lower serum triglycerides and C-reactive protein. [22]